Stock RYTM RHYTHM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
38.28 USD +0.34% Intraday chart for Rhythm Pharmaceuticals, Inc. +0.71% -16.73%
Apr. 18 Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating MT
Apr. 01 Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock MT

Business Summary

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Number of employees: 226

Sales per Business

USD in Million2022Weight2023Weight Delta
Therapeutics
100.0 %
24 100.0 % 77 100.0 % +227.56%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
80.6 %
24 100.0 % 62 80.6 % +164.09%
Other
11.5 %
-- 9 11.5 % -
Germany
7.8 %
-- 6 7.8 % -

Managers

Managers TitleAgeSince
David Meeker CEO
 Chief Executive Officer 69 15-10-31
Hunter Smith DFI
 Director of Finance/CFO 56 17-06-30
Joseph Shulman CTO
 Chief Tech/Sci/R&D Officer 49 20-07-26
Dana Washburn CTO
 Chief Tech/Sci/R&D Officer 61 22-09-25
David Connolly IRC
 Investor Relations Contact - 19-04-30
Christopher German AUD
 Comptroller/Controller/Auditor 53 23-02-28
Elisabeth Crönert-Bendell PRN
 Corporate Officer/Principal - 21-03-31
Pamela Cramer HRO
 Human Resources Officer 50 21-07-25
Jim Flaherty LAW
 General Counsel - 19-06-30
Yann Mazabraud PRN
 Corporate Officer/Principal 51 20-10-04

Members of the board

Members of the board TitleAgeSince
Christophe Jean BRD
 Director/Board Member 67 15-03-31
Jennifer Good BRD
 Director/Board Member 59 19-06-18
David McGirr BRD
 Director/Board Member 69 15-10-31
Camille Bedrosian BRD
 Director/Board Member 71 20-12-08
Ed Mathers Mathers BRD
 Director/Board Member 64 13-03-20
David Meeker CEO
 Chief Executive Officer 69 15-10-31
Lynn Tetrault BRD
 Director/Board Member 61 20-12-08
Stuart Arbuckle BRD
 Director/Board Member 58 19-07-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 60,963,518 57,367,172 ( 94.10 %) 0 94.10 %

Shareholders

NameEquities%Valuation
PRIMECAP Management Co.
13.39 %
8,052,648 13.39 % 349 M $
PRIMECAP Management Co.
13.39 %
8,052,648 13.39 % 349 M $
Baker Bros. Advisors LP
10.64 %
6,398,365 10.64 % 277 M $
Baker Bros. Advisors LP
10.64 %
6,398,365 10.64 % 277 M $
BlackRock Advisors LLC
9.016 %
5,422,165 9.016 % 235 M $
RA Capital Management LP
8.863 %
5,330,412 8.863 % 231 M $
RA Capital Management LP
8.863 %
5,330,412 8.863 % 231 M $
Goldman Sachs Asset Management LP
8.394 %
5,047,934 8.394 % 219 M $
Perceptive Advisors LLC
5.435 %
3,268,579 5.435 % 142 M $
Vanguard Fiduciary Trust Co.
5.366 %
3,226,938 5.366 % 140 M $

Company contact information

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street 12th floor

02116-3748, Boston

+857 264 4280

http://www.rhythmtx.com
address Rhythm Pharmaceuticals, Inc.(RYTM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Rhythm Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.28 USD
Average target price
57.33 USD
Spread / Average Target
+49.77%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
RHYTHM PHARMACEUTICALS, INC. Stock Rhythm Pharmaceuticals, Inc.
-16.73% 2.33B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RYTM Stock
  4. Company Rhythm Pharmaceuticals, Inc.